These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

255 related articles for article (PubMed ID: 27862841)

  • 1. The ubiquitin ligase UBE4A inhibits prostate cancer progression by targeting interleukin-like EMT inducer (ILEI).
    Sun Y; Jia X; Gao Q; Liu X; Hou L
    IUBMB Life; 2017 Jan; 69(1):16-21. PubMed ID: 27862841
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Covalent dimerization of interleukin-like epithelial-to-mesenchymal transition (EMT) inducer (ILEI) facilitates EMT, invasion, and late aspects of metastasis.
    Kral M; Klimek C; Kutay B; Timelthaler G; Lendl T; Neuditschko B; Gerner C; Sibilia M; Csiszar A
    FEBS J; 2017 Oct; 284(20):3484-3505. PubMed ID: 28837266
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Poly r(C) binding protein (PCBP) 1 expression is regulated by the E3 ligase UBE4A in thyroid carcinoma.
    Zhang MP; Zhang WS; Tan J; Zhao MH; Lian LJ; Cai J
    Biosci Rep; 2017 Oct; 37(5):. PubMed ID: 28963376
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The ubiquitin ligase TRIM56 inhibits ovarian cancer progression by targeting vimentin.
    Zhao L; Zhang P; Su XJ; Zhang B
    J Cell Physiol; 2018 Mar; 233(3):2420-2425. PubMed ID: 28771721
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The FAM3C locus that encodes interleukin-like EMT inducer (ILEI) is frequently co-amplified in MET-amplified cancers and contributes to invasiveness.
    Schmidt U; Heller G; Timelthaler G; Heffeter P; Somodi Z; Schweifer N; Sibilia M; Berger W; Csiszar A
    J Exp Clin Cancer Res; 2021 Feb; 40(1):69. PubMed ID: 33596971
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Interleukin-like EMT inducer (ILEI) promotes melanoma invasiveness and is transcriptionally up-regulated by upstream stimulatory factor-1 (USF-1).
    Noguchi K; Dincman TA; Dalton AC; Howley BV; McCall BJ; Mohanty BK; Howe PH
    J Biol Chem; 2018 Jul; 293(29):11401-11414. PubMed ID: 29871931
    [TBL] [Abstract][Full Text] [Related]  

  • 7. ILEI drives epithelial to mesenchymal transition and metastatic progression in the lung cancer cell line A549.
    Song Q; Sheng W; Zhang X; Jiao S; Li F
    Tumour Biol; 2014 Feb; 35(2):1377-82. PubMed ID: 24072492
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Interleukin-like EMT inducer regulates partial phenotype switching in MITF-low melanoma cell lines.
    Noguchi K; Dalton AC; Howley BV; McCall BJ; Yoshida A; Diehl JA; Howe PH
    PLoS One; 2017; 12(5):e0177830. PubMed ID: 28545079
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The ubiquitin ligase TRIM25 inhibits hepatocellular carcinoma progression by targeting metastasis associated 1 protein.
    Zang HL; Ren SN; Cao H; Tian XF
    IUBMB Life; 2017 Oct; 69(10):795-801. PubMed ID: 28861931
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The interleukin-like epithelial-mesenchymal transition inducer ILEI exhibits a non-interleukin-like fold and is active as a domain-swapped dimer.
    Jansson AM; Csiszar A; Maier J; Nyström AC; Ax E; Johansson P; Schiavone LH
    J Biol Chem; 2017 Sep; 292(37):15501-15511. PubMed ID: 28751379
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Periostin Mediates TGF-β-Induced Epithelial Mesenchymal Transition in Prostate Cancer Cells.
    Hu Q; Tong S; Zhao X; Ding W; Gou Y; Xu K; Sun C; Xia G
    Cell Physiol Biochem; 2015; 36(2):799-809. PubMed ID: 26021267
    [TBL] [Abstract][Full Text] [Related]  

  • 12. TGFβ promotes breast cancer stem cell self-renewal through an ILEI/LIFR signaling axis.
    Woosley AN; Dalton AC; Hussey GS; Howley BV; Mohanty BK; Grelet S; Dincman T; Bloos S; Olsen SK; Howe PH
    Oncogene; 2019 May; 38(20):3794-3811. PubMed ID: 30692635
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CX3CL1 increases invasiveness and metastasis by promoting epithelial-to-mesenchymal transition through the TACE/TGF-α/EGFR pathway in hypoxic androgen-independent prostate cancer cells.
    Tang J; Xiao L; Cui R; Li D; Zheng X; Zhu L; Sun H; Pan Y; Du Y; Yu X
    Oncol Rep; 2016 Feb; 35(2):1153-62. PubMed ID: 26718770
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hypoxia regulates ANXA1 expression to support prostate cancer cell invasion and aggressiveness.
    Bizzarro V; Belvedere R; Migliaro V; Romano E; Parente L; Petrella A
    Cell Adh Migr; 2017 May; 11(3):247-260. PubMed ID: 27834582
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Notch-4 silencing inhibits prostate cancer growth and EMT via the NF-κB pathway.
    Zhang J; Kuang Y; Wang Y; Xu Q; Ren Q
    Apoptosis; 2017 Jun; 22(6):877-884. PubMed ID: 28374086
    [TBL] [Abstract][Full Text] [Related]  

  • 16. ILEI is an important intermediate participating in the formation of TGF-β1-induced renal tubular EMT.
    Zhao X; Luo G; Fan Y; Ma X; Zhou J; Jiang H
    Cell Biochem Funct; 2018 Mar; 36(2):46-55. PubMed ID: 29336056
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Expression of Tripartite Motif-Containing Proteactiin 11 (TRIM11) is Associated with the Progression of Human Prostate Cancer and is Downregulated by MicroRNA-5193.
    Pan Y; Zhang R; Chen H; Chen W; Wu K; Lv J
    Med Sci Monit; 2019 Jan; 25():98-106. PubMed ID: 30608062
    [TBL] [Abstract][Full Text] [Related]  

  • 18. ILEI: a novel marker for epithelial-mesenchymal transition and poor prognosis in colorectal cancer.
    Gao ZH; Lu C; Wang ZN; Song YX; Zhu JL; Gao P; Sun JX; Chen XW; Wang MX; Dong YL; Xu HM
    Histopathology; 2014 Oct; 65(4):527-38. PubMed ID: 24738665
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Down-regulation of E-cadherin enhances prostate cancer chemoresistance via Notch signaling.
    Wang W; Wang L; Mizokami A; Shi J; Zou C; Dai J; Keller ET; Lu Y; Zhang J
    Chin J Cancer; 2017 Mar; 36(1):35. PubMed ID: 28356132
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ubiquitin ligase CHIP functions as an oncogene and activates the AKT signaling pathway in prostate cancer.
    Cheng L; Zang J; Dai HJ; Li F; Guo F
    Int J Oncol; 2018 Jul; 53(1):203-214. PubMed ID: 29693147
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.